DNMT1 and osteosarcoma: Moreover, treatment with 5-Aza-2′-deoxycytidine (5-aza), a DNMT inhibitor, was shown to induce senescence in many solid tumours, including osteosarcoma, lung mesothelioma, hepatocellular carcinoma, and breast cancer [40,45,46,47].